eisai to present latest data on lemborexant at the 37th annual sleep 2023 meeting – eisai china lnc.-爱游戏app官网入口
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: dayvigo®), will be given at the 37th annual meeting of the associated professional sleep societies (sleep 2023), to be held from june 3 to 7, 2023 in indianapolis, in, the united states.
major poster presentations include new data about the effects of lemborexant on obstructive sleep apnea (poster numbers: #298, 299 and 300).
eisai considers neurology, including insomnia, a therapeutic area of focus. eisai strives to create innovative products as soon as possible in therapeutic areas with high unmet medical needs, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.
